7 / 8
Page 25
Notes:
allied
academies
July 23-25, 2018 | Moscow, Russia
12
th
World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume: 3
Background:
Neoadjuvant treatment (NAT) followed by
surgery has currently become a part of standard care for
patients with locally advanced breast cancer. Postopeartive
treatment is generally established on the same detective
biomarkers (estrogen receptor, progesterone receptor, HER2
and Ki67) evaluated in Core Needle Biopsy (CNB) before
NAT. The aim of this study was to investigate whether NAT
induces some selective changes in the breast biomarkers.
Methods:
We collected the appropriate data for 52
patients that conform to the requirements from the
personal hospital files, since 2007 until 2016. Formalin
fixed paraffin embedded samples or fresh tissue samples
were used from tumors before and after surgery. Ki67
was evaluated using immunohistochemically testing. The
antibody-antigen interaction is observed using chromogenic
detection, an enzyme (DAB) conjugated to the antibody to
produce a colored precipitate at the location of the antigen.
Results:
Mean age of patients was 52.3 ± 13.9. Ethnicity: 28
(53.8%) women were Jews and 24 (46.2) were Arabs. 56%
of women were premenopausal, 44% postmenopausal.
Lumpectomy was done in 39 (75%) of patients while the others
(25%) hadmastectomy. Mean level of Ki67 in the primary tumor
was 34.8 ± 26.1 %, after NAT was 17.8 ± 22.9% (P < 0.001).
Conclusions:
In this study we found significant changes in
Ki67 expression between the pretreatment biopsy specimens
and the resected specimens of breast cancer patients who
underwent neoadjuvant therapy. This discordance in the
expressionofKi6mayaffectthechoiceofpostoperativeadjuvant
treatment and may be used as a prognostic factor for response.
Speaker Biography
Jamal Zidan earned his doctorate in medicine (MD) at the Semmelweis University in
Budapest, Hungary. His speciality is Oncology. He is a full professor at the Faculty of
Medicine intheGalilee,Safed,Bar-llanUniversity, Israel.HeadofOncologyDivisionatZiv
Medicalcenter,Safed, Israel.Prof.Zidanhasover170publications.Hehasreceivedmany
honors as: “ Eminent Scientist & Outstanding Scholar of the year 2001” International
award of IRPC; International Research Promotion Council Asia-Pacific Chapter, World
Scientists Forum International Award, Gold Medal. His main research interest is
molecular biomarkers, targeting therapy, breast cancer and other issues in cancer.
e:
zidan.j@ziv.health.gov.ilJamal Zidan
1
Maayan Galer
2
Sergio Shvalb
3
Bar-Ilan University, Israel
Comparison between Ki-67 biomarker expression in primary Breast Cancer before and after
neoadjuvant therapy